Knockdown of UBE2C sensitized the cells to pharmacological treatments with irinotecan in colorectal cancer [30] and increased the sensitivity of cancer cells to epirubicin and docetaxel in breast cancer [31]. Here, UBE2C is linked to breast cancer.